Helicobacter Pylori Gastritis and Its Relation to Metabolic Syndrome Components
NCT06935955 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 114
Last updated 2025-04-20
Summary
2.2 Aim
1. To evaluate the association between H. pylori infection and the components of metabolic syndrome.
2. To assess the relationship between the histopathologic features of chronic gastritis evaluated using USS and the components of metabolic syndrome in both H. pylori-positive and H. pylori-negative patients.
2.4. 2- Study Setting: Department of Pathology, Faculty of Medicine, Assiut University.
c. Sample Size Calculation: Sample size was calculated using Epi- Info7. Based on The H. pylori-positive patients were more likely to develop dyslipidemia, and 77.47% of individuals testing positive for H. pylori have higher total cholesterol levels (11). With a confidence limit of 5% and a confidence level of 80%, the minimum number of patients required for this study is 114 cases
2.4.4 -Study tools The study will include 114 patients diagnosed with gastritis in the Gastroenterology unit and scheduled for upper gastrointestinal endoscopy with stomach biopsy. Written informed consent will be obtained from all patients participating in the study.
All subjects will be asked to complete a medical history questionnaire, followed by a physical examination (height, body weight, waist circumference, and blood pressure) and laboratory investigations (fasting blood glucose, liver function test, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol( The endoscopy will be carried out by the same specialist, and it will assess chronic and acute gastritis, atrophic gastritis, and metaplasia. The endoscopist will obtain five biopsy samples: two from the antrum, two from the corpus, and one from the incisura.
All biopsies will be processed at the Pathology Department laboratory and embedded in paraffin blocks. For histological examination, two tissue sections will be stained: hematoxylin and eosin (H\&E) and Giemsa stain. Each sample will undergo a double-blind review by two independent pathologists according to the USS (HP, neutrophils, mononuclear cells, atrophy, and intestinal metaplasia), and each variable will be graded semi-quantitatively.
Statistical analysis using suitable tests will be used to assess our results.
2.4.5 -Research outcome measures:
1. Primary (main): to evaluate the association between H.pylori gastritis and its relation to metabolic syndrome components
2. Secondary (subsidiary):
2.5-Data management and analysis : Data collection All subjects will be asked to complete a medical history questionnaire, followed by a physical examination (height, body weight, waist circumference, and blood pressure) and laboratory investigations (fasting blood glucose, liver function test, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.
Computer software Statistical package for social science (SPSS) program v. 25 (IBM, August 2017).
Conditions
- Gastritis
Interventions
- DIAGNOSTIC_TEST
-
upper endoscopy
All subjects will be asked to complete a medical history questionnaire, followed by physical examination (height, body weight, waist circumference and blood pressure), and laboratory investigations (fasting blood glucose, liver function test, total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol( The endoscopy will be carried out by the same specialist, with assessment of chronic and acute gastritis, atrophic gastritis and metaplasia. The endoscopist will obtain five biopsies samples, two from the antrum, two from the corpus and one from incisura. All biopsies will be processed at the Pathology Department laboratory and embedded in paraffin blocks. For histological examination, two sets of tissue sections will be stained: one with hematoxylin and eosin (H\&E) and the other with Giemsa stain. Each sample will undergo a double-blind review by two independent pathologists according to the USS (HP, neutrophils, mononuclear cells, atro
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-01
- Primary Completion
- 2026-05-01
- Completion
- 2027-05-01
More Related Trials
-
Effect of Hp Infection on the Quality of Gastric Mucosa Preparation
NCT05527496 ·Status: UNKNOWN
-
The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study
NCT02933229 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Association Between Helicobacter Pylori and Inflammatory Bowel Disease
NCT03820284 ·Status: COMPLETED
-
Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms
NCT06422052 ·Status: RECRUITING
-
Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa in Autoimmune Gastritis
NCT05238181 ·Status: ENROLLING_BY_INVITATION
-
HELICOBACTER PYLORI INFECTION IN TYPE 2 DIABETES MELLITUS IN ASSIUT UNIVERSITY HOSPITAL
NCT05789550 ·Status: UNKNOWN
-
The Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology
NCT04029441 ·Status: UNKNOWN
-
Prevalence of H. Pylori Gastritis in Sleeve Gastrectomy Specimens
NCT05101395 ·Status: COMPLETED
-
Difference of Gastric Microbiota in the Process of Correa's Model.
NCT02833363 ·Status: UNKNOWN
-
Helicobacter Pylori and it's Hematological Impact
NCT03629587 ·Status: COMPLETED
-
Correlation Between Endoscopic Findings And Helicobacter Pylori Infection In Chronic Kidney Disease Patients
NCT05927766 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Immunohistochemical Expression of Heparanase in Helicobacter Pylori-Associated Chronic Gastritis
NCT05073614 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy
NCT06269380 ·Status: COMPLETED ·Phase: NA
-
Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy
NCT05444439 ·Status: COMPLETED ·Phase: NA
-
Specimen Collection Study for H. Pylori Testing
NCT02970110 ·Status: COMPLETED
-
The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy
NCT00983034 ·Status: COMPLETED ·Phase: NA
-
Duodenal Microbiota in Functional Dyspepsia
NCT06326918 ·Status: RECRUITING
-
The Relationship Between Helicobacter Pylori Infection and Inflammatory Bowel Diseases: A Real-life Observation
NCT04708405 ·Status: COMPLETED
-
Investigation on Diagnosis and Treatment of Helicobacter Pylori Infection by Gastroenterologists in Shandong Province
NCT04918134 ·Status: COMPLETED
-
Effect of H. Pylori Eradication on the Reversibility of Atrophic Gastritis and Intestinal Metaplasia in Korean Patients
NCT02691637 ·Status: COMPLETED
-
The Effect of PPI Therapy on the Result of Helicobacter Pylori Diagnostic Tests
NCT01278901 ·Status: UNKNOWN
-
Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy
NCT05790525 ·Status: COMPLETED ·Phase: PHASE4
-
White Light Endoscopy and Magnifying Endoscopy in Assessing the Status of Hp Infection
NCT06397066 ·Status: RECRUITING
-
The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
NCT04029493 ·Status: UNKNOWN
-
Detection of Helicobacter Pylori Infection by High Resolution Endoscopy
NCT01434992 ·Status: COMPLETED